Nomenclature for human CYP2D6 alleles

被引:381
作者
Daly, AK
Brockmoller, J
Broly, F
Eichelbaum, M
Evans, WE
Gonzalez, FJ
Huang, JD
Idle, JR
IngelmanSundberg, M
Ishizaki, T
JacqzAigrain, E
Meyer, UA
Nebert, DW
Steen, VM
Wolf, CR
Zanger, UM
机构
[1] HUMBOLDT UNIV BERLIN, INST KLIN PHARMAKOL, KLINIKUM CHARITE, D-10098 BERLIN, GERMANY
[2] CTR HOSP REG & UNIV LILLE, HOP CALMETTE, LAB BIOCHIM & BIOL MOL, F-59037 LILLE, FRANCE
[3] DR MARGARETE FISCHER BOSCH INST CLIN PHARMACOL, D-70376 STUTTGART, GERMANY
[4] ST JUDE CHILDRENS RES HOSP, DEPT PHARMACEUT, MEMPHIS, TN 38101 USA
[5] NCI, MOLEC CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA
[6] NATL CHENG KUNG UNIV, DEPT PHARMACOL, TAINAN 70101, TAIWAN
[7] KAROLINSKA INST, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN
[8] INT MED CTR JAPAN, RES INST, DEPT CLIN PHARMACOL, SHINJUKU KU, TOKYO 162, JAPAN
[9] HOP ROBERT DEBRE, INSERM U120, F-75019 PARIS, FRANCE
[10] HOP ROBERT DEBRE, DEPT CLIN PHARMACOL, F-75019 PARIS, FRANCE
[11] UNIV BASEL, BIOCTR, ABT PHARMAKOL, CH-4056 BASEL, SWITZERLAND
[12] UNIV CINCINNATI, MED CTR, DEPT ENVIRONM HLTH, CINCINNATI, OH 45267 USA
[13] HAUKELAND HOSP, CTR MOL MED, DR EINAR MARTENS RES GRP BIOL PSYCHIAT, N-5021 BERGEN, NORWAY
[14] UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
allele nomenclature; CYP2D6;
D O I
10.1097/00008571-199606000-00001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
To standardize CYP2D6 allele nomenclature, and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described, Based on recommendations for human genome nomenclature, we propose that alleles be designated by CYP2D6 followed by an asterisk and a combination of roman letters and arabic numerals distinct for each allele with the number specifying the key mutation and, where appropriate, a letter specifying additional mutations, Criteria for classification as a separate allele and protein nomenclature are also presented.
引用
收藏
页码:193 / 201
页数:9
相关论文
共 40 条
  • [1] AKLILLU E, 1995, UNPUB FREQUENT DISTR
  • [2] DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE
    BROLY, F
    MEYER, UA
    [J]. PHARMACOGENETICS, 1993, 3 (03): : 123 - 130
  • [3] An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis
    Broly, F
    Marez, D
    Sabbagh, N
    Legrand, M
    Millecamps, S
    LoGuidice, JM
    Boone, P
    Meyer, UA
    [J]. PHARMACOGENETICS, 1995, 5 (06): : 373 - 384
  • [4] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION
    BROLY, F
    GAEDIGK, A
    HEIM, M
    EICHELBAUM, M
    MORIKE, K
    MEYER, UA
    [J]. DNA AND CELL BIOLOGY, 1991, 10 (08) : 545 - 558
  • [5] THE ROLE OF INDIVIDUAL HUMAN CYTOCHROMES-P450 IN DRUG-METABOLISM AND CLINICAL-RESPONSE
    CHOLERTON, S
    DALY, AK
    IDLE, JR
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 1992, 13 (12) : 434 - 439
  • [6] ANALYSIS OF THE CYP2D6 GENE IN RELATION TO DEBRISOQUIN AND DESIPRAMINE HYDROXYLATION IN A SWEDISH POPULATION
    DAHL, ML
    JOHANSSON, I
    PALMERTZ, MP
    INGELMANSUNDBERG, M
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (01) : 12 - 17
  • [7] DAHL ML, 1995, J PHARMACOL EXP THER, V274, P516
  • [8] GENETIC AND METABOLIC CRITERIA FOR THE ASSIGNMENT OF DEBRISOQUINE 4-HYDROXYLATION (CYTOCHROME-P4502D6) PHENOTYPES
    DALY, AK
    ARMSTRONG, M
    MONKMAN, SC
    IDLE, ME
    IDLE, JR
    [J]. PHARMACOGENETICS, 1991, 1 (01): : 33 - 41
  • [9] DALY AK, 1995, HUM GENET, V95, P337
  • [10] DALY AK, 1996, IN PRESS PHARMACOGEN, V6